Abstract

BackgroundPichia pastoris shows physiological advantages in producing recombinant proteins, compared to other commonly used cell factories. This yeast is mostly grown in dynamic cultivation systems, where the cell’s environment is continuously changing and many variables influence process productivity. In this context, a model capable of explaining and predicting cell behavior for the rational design of bioprocesses is highly desirable. Currently, there are five genome-scale metabolic reconstructions of P. pastoris which have been used to predict extracellular cell behavior in stationary conditions.ResultsIn this work, we assembled a dynamic genome-scale metabolic model for glucose-limited, aerobic cultivations of Pichia pastoris. Starting from an initial model structure for batch and fed-batch cultures, we performed pre/post regression diagnostics to ensure that model parameters were identifiable, significant and sensitive. Once identified, the non-relevant ones were iteratively fixed until a priori robust modeling structures were found for each type of cultivation. Next, the robustness of these reduced structures was confirmed by calibrating the model with new datasets, where no sensitivity, identifiability or significance problems appeared in their parameters. Afterwards, the model was validated for the prediction of batch and fed-batch dynamics in the studied conditions.Lastly, the model was employed as a case study to analyze the metabolic flux distribution of a fed-batch culture and to unravel genetic and process engineering strategies to improve the production of recombinant Human Serum Albumin (HSA). Simulation of single knock-outs indicated that deviation of carbon towards cysteine and tryptophan formation improves HSA production. The deletion of methylene tetrahydrofolate dehydrogenase could increase the HSA volumetric productivity by 630%. Moreover, given specific bioprocess limitations and strain characteristics, the model suggests that implementation of a decreasing specific growth rate during the feed phase of a fed-batch culture results in a 25% increase of the volumetric productivity of the protein.ConclusionIn this work, we formulated a dynamic genome scale metabolic model of Pichia pastoris that yields realistic metabolic flux distributions throughout dynamic cultivations. The model can be calibrated with experimental data to rationally propose genetic and process engineering strategies to improve the performance of a P. pastoris strain of interest.

Highlights

  • Pichia pastoris shows physiological advantages in producing recombinant proteins, compared to other commonly used cell factories

  • Simulation Analysis of the metabolic flux distribution during key stages of a dynamic cultivation After the calibration of the fed-batch model with the dataset used for checking its robustness, we evaluated the central metabolic flux distributions at three different stages of the cultivation: exponential growth during the batch phase (~20 h), ethanol and arabitol consumption during glucose starvation phase (~27.5 h) and controlled growth during the feeding phase (~45 h)

  • Little attention has been given to the actual metabolic flux distribution that these reconstructions yield and how they evolve in a dynamic environment

Read more

Summary

Introduction

Pichia pastoris shows physiological advantages in producing recombinant proteins, compared to other commonly used cell factories. This yeast is mostly grown in dynamic cultivation systems, where the cell’s environment is continuously changing and many variables influence process productivity. In contrast to S. cerevisiae, P. pastoris exhibits a Crabtree-negative phenotype, showing a reduced synthesis of undesirable products, like ethanol, in glucoselimited conditions [12, 13] It shows a lower basal secretion of proteins when compared to other yeasts, which makes downstream processing easier [13, 14]. As proof of its technical feasibility and adequacy, two recombinant proteins produced in this cell factory have already been approved by the FDA for medical purposes [10, 19]

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.